Loading...
Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Genestreti, G Tiseo, M Kenmotsu, H Kazushige, W Di Battista, M Cavallo, G Carloni, F Bongiovanni, A Burgio, M Casanova, C
Genestreti, G
Tiseo, M
Kenmotsu, H
Kazushige, W
Di Battista, M
Cavallo, G
Carloni, F
Bongiovanni, A
Burgio, M
Casanova, C
Citations
Altmetric:
Abstract
Patients with small-cell lung cancer (SCLC) that progresses after first-line (FL) chemotherapy have a poor prognosis and second-line (SL) chemotherapy has limited efficacy. Patients whose disease relapses/progresses > 90 days after FL platinum-based treatment are considered platinum-sensitive and could be rechallenged with a similar regimen. We conducted a multicenter retrospective analysis to evaluate outcomes of SCLC patients rechallenged with platinum/etoposide.
Description
Date
2015-04-24
Publisher
Collections
Keywords
Type
Article
Citation
Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis. 2015: Clin Lung Cancer